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Development of an antibody fragment that
stabilizes GPCR/G-protein complexes
Shoji Maeda1, Antoine Koehl2, Hugues Matile3, Hongli Hu1,2, Daniel Hilger1, Gebhard F.X. Schertler4,
Aashish Manglik5,6, Georgios Skiniotis 1,2, Roger J.P. Dawson 3 & Brian K. Kobilka1
Single-particle cryo-electron microscopy (cryo-EM) has recently enabled high-resolution
structure determination of numerous biological macromolecular complexes. Despite this
progress, the application of high-resolution cryo-EM to G protein coupled receptors (GPCRs)
in complex with heterotrimeric G proteins remains challenging, owning to both the relative
small size and the limited stability of these assemblies. Here we describe the development of
antibody fragments that bind and stabilize GPCR-G protein complexes for the application of
high-resolution cryo-EM. One antibody in particular, mAb16, stabilizes GPCR/G-protein
complexes by recognizing an interface between Gα and Gβγ subunits in the heterotrimer, and
confers resistance to GTPγS-triggered dissociation. The unique recognition mode of this
antibody makes it possible to transfer its binding and stabilizing effect to other G-protein
subtypes through minimal protein engineering. This antibody fragment is thus a broadly
applicable tool for structural studies of GPCR/G-protein complexes.
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G-protein coupled receptors (GPCRs) make up the largestreceptor family in the human genome, comprising around800 members. GPCRs are expressed ubiquitously and play
essential roles of signal transduction in response to a wide variety
of extracellular stimuli such as photons, ions, neurotransmitters,
hormones and proteins. Given their numerous physiological
roles, GPCRs are implicated in numerous diseases and ~30% of
marketed drugs are targeting this receptor family1. Recent
advances in GPCR crystallography have led to high-resolution
structures of G-protein2 and arrestin3 complexes, which have
enhanced our understanding of the structural details underlying
ligand binding and signal transduction at the atomic level. The
first crystal structure of a GPCR/G-protein complex was that of
the β2 adrenergic receptor in complex with stimulatory G-protein,
Gs (β2AR/Gs)2. This was later followed by the crystal structure of
A2A adenosine receptor in complex with miniGs (A2AR/miniGs)
in which a highly engineered Gαs that consists of only the Gα ras-
like domain was used in place of the full heterotrimer2,4. The fact
that such drastic protein engineering is needed to obtain dif-
fraction quality crystals reflects the difficulty inherent in
GPCR–G-protein complex crystallography. Despite the techno-
logical advancement, crystallographic studies of these complexes
remains extremely difficult. More recently, single-particle cryo-
electron microscopy (cryo-EM) has emerged as an alternative
technique with the ability to provide near-atomic resolution
maps, as demonstrated for two class B GPCRs3,5,6 both in com-
plex with Gs: the glucagon-like peptide1 receptor/Gs (Glp-
1R/Gs)6,7 as well as the calcitonin receptor/Gs (CTR/Gs)5. These
studies have highlighted the possibility of employing cryo-EM to
obtain the structures of GPCR-G protein complexes. Compared
to class A GPCRs, class B receptors include a structured extra-
cellular domain that may aid in particle alignment. Furthermore,
for Gs proteins, Nb352 stabilizes these complexes against GTPγS
by stabilizing an interface between the Ras-like domain of the Gαs
subunit and the Gβ subunit. These factors make class B GPCR/Gs
protein complexes more tractable targets for cryo-EM compared
to class A or other G-protein subtype complexes.
Apart from the GPCR/Gs complex, the only structure available
at high-resolution has been limited to the MetaII rhodopsin/GαCt
where the last 11-amino-acid fragment of Gtransducin was co-
crystalized with the activated rhodopsin8. Although in silico
analyses using this complex have provided insights into the
conformational changes that allow Gi coupling as well as general
principles for G protein coupling specificity9,10, experimental
structures of other G-protein complexes are invaluable to
understand how receptors selectively engage one G-protein
subtype over others. G-protein mimetic nanobodies have been
used as a surrogate to capture the active conformation of a
receptor11–14, but it may require an extensive effort to find such
nanobodies and the trapped conformation may not necessarily
represent the G-protein engaged state.
Here we describe the development of an antibody, termed
mAb16, that recognizes the heterotrimeric Gi/o type G protein
and enhances the stability of GPCR-Gi/o complexes, while
simultaneously adding an asymmetric feature that may aid with
cryo-EM particle projection alignment. As antibodies typically
bind to their targets in a rigid manner, such an antibody would be
expected to enable structure determination of GPCR/G-protein
complexes by cryo-EM. mAb16 recognizes a unique epitope,
binding at the interface between the α and β subunits of het-
erotrimeric Gi. While the antibody confers extra stability to
GPCR/Gi/o complex as well as increased resistance to GTPγS-
triggered dissociation of the complex in a manner similar to Nb35
for Gs, mAb16 and Nb35 bind to completely different epitopes.
We have recently succeeded in obtaining a near-atomic resolution
map of the mu-opioid receptor (μOR)/Gi complex using this
antibody fragment15. Although this antibody is specific against
Gi/o-family G-proteins, its ability to bind and stabilize the het-
erotrimer can be transferred to other G-protein subtypes through
a simple protein engineering strategy.
Results
Selection of monoclonal antibodies. Despite exhaustive attempts
to crystalize a complex between rhodopsin and heterotrimeric
Gi116, we were unsuccessful in producing diffraction quality
crystals. We presumed that this was due to the flexibility of the
alpha-helical domain of Gαi1 as this domain separates from Ras-
like domain and becomes flexible upon receptor-mediated acti-
vation in the nucleotide-free state17,18. We then set out to discover
antibodies that could reduce this flexibility and facilitate crystal-
lographic and cryo-EM structural studies of the complex. Mice
were immunized with purified rhodopsin/Gi1 complex and
hybridoma cells were prepared from the isolated mice splenocytes.
Clones that showed enzyme-linked immunosorbent assay (ELISA)
and immunoprecipitation positive reaction were screened further
using an analytical size-exclusion chromatography (SEC) assay
with purified monoclonal antibodies. Most of the SEC-positive
clones were Gβγ-binders, reflecting that it is the most stable and
rigid component of the complex (Fig. 1a, c). Interestingly, we
found a single clone that binds and confers GTPγS resistance to
the rhodopsin/Gi1 complex (Fig. 1a, b). Based on the clone
identification number, we named its antibody mAb16. Notably,
this clone does not show binding to any single component of Gi1,
but binds specifically to the intact heterotrimeric form of Gi1,
suggesting that it binds a composite epitope at the interface
between Gαi1 and Gβγ subunits (Fig. 1c). We provide amino-acid
sequence of mAb16 in the Supplementary Note 1.
Crystal structure of Gi1/scFv16. In order to better understand
the recognition mode of mAb16, we crystallized a fully soluble
heterotrimeric Gi1 in complex with mAb16 fragments. We tried
both a Fab fragment (Fab16) and single-chain variable fragment
(scFv16) derived from mAb16. Both Gi1/Fab16 and Gi1/scFv16
complexes formed crystals but only the scFv16 version diffracted
to high resolution, presumably due to the intrinsic flexibility of
the linker between the variable and the constant domain of the
Fab19. The crystal structure of the Gi1/scFv16 complex was solved
at 2.0 Å by molecular replacement using Gi1 (PDB ID: 1GP2) and
an scFv fragment (PDB ID: 4NKD) as search models (Table 1).
The overall structure of Gi1 in complex with scFv16 is very similar
to Gi1 alone (Fig. 2a). The relative position of Ras-like domain
and alpha-helical domain of Gαi1 moves closer to Gβ1 by a small
rotation movement around the αN-b1 junction (Fig. 2b). This
slight movement leads to two additional interactions between
Thr182 of Gαi1 and Asn119 of Gβ1, and Arg205 of Gαi1 and
Thr143 of Gβ1, located in Switch I and Switch II region,
respectively (Fig. 2b). This could be due to the tighter association
between these two subunits mediated by scFv16, although it may
be the consequence of different crystal contacts between Gi1 alone
and Gi1/scFv16. The structure of the Gi1/scFv16 complex shows
that scFv16 recognizes an epitope composed of the terminal part
of the αN helix of Gαi1 as well as part of the Gβ1 subunit (Fig. 2c,
Supplementary Fig. 1). The complementarity-determining region
3 of the heavy chain (CDR-H3) extends to interact with Gβ1 with
its tip and Gαi1 with its side. CDR2-H2 and CDR-H1 support the
interaction with Gαi1 and Gβ1, respectively by making hydrogen
bonds and van der Waals contacts. CDR-L1 is exceptionally long
and makes extensive contact with the edge of the αN helix
together with CDR-L3 (Fig. 2c). There is no obvious interaction
between scFv16 and Gγ2 subunit.
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As the α subunits of all Gi/o family members have high
sequence similarity at the epitope residues in the αN helix
(Fig. 3a) and can form a complex with Gβ1γ2, we expected that
Fab16 would bind to all Gi/o family proteins. Using analytical
fluorescent SEC, we show that Fab16 can bind to five different Gi/
o type G-proteins but not Gs, as it has poor sequence similarity to
Gi/o members at this epitope region (Fig. 3b).
Application to other GPCR-Gi/o complexes. Since Fab16 was
initially isolated as a stabilizing agent that confers resistance to
GTPγS triggered dissociation to a rhodopsin/Gi1 complex and
was later found to bind to a panel of Gi/o family members, we
investigated whether it confers the same GTPγS resistance to
other Gi/o type GPCR complexes. We chose a μ-opioid receptor/
Gi1 (μOR/Gi1) and an M2 muscarinic acetylcholine receptor/GoA
(M2R/GoA) as representative family A Gi/o-coupling GPCR
complexes. Purified μOR/Gi1 or M2R/GoA complex solubilized in
detergent was incubated with GTPγS in the presence or absence
of Fab16, then analysed for dissociation by analytical SEC. Both
μOR/Gi1 and M2R/GoA complexes showed a leftward peak shift
upon incubating with Fab16, indicating its binding and also
became GTPγS resistant, as they showed much less dissociation
in the presence of Fab16 than the complex alone (Fig. 3c). These
data with GPCR/Gi/o complexes are consistent with the binding
experiments of Fab16 with G-protein alone, and indicate that it
stabilizes Gi/o type GPCR complexes in general. In order to show
the applicability of scFv16 to structural analysis of GPCR-G
protein complexes, we have recently solved a near-atomic reso-
lution map of μOR/Gi1 complex using scFv1615. The presence of
scFv16 enhanced complex stability towards specimen vitrification
for cryo-EM, thereby enabling quality single-particle
reconstructions.
Influence of Fab16 on nucleotide binding. In order to further
investigate mAb16 for its protection mechanism against GTPγS,
we monitored the binding kinetics of GTPγS to nucleotide-free
M2R/GoA complex. In the absence of Fab16, BODIPY-FL-GTPγS,
a fluorescent analogue of GTPγS, binds to the complex with fast
kinetics reflecting its ability to bind and trigger the dissociation of
the complex. In contrast, BODIPY-FL-GTPγS binds to M2R/GoA/
Fab16 complex ~70 times slower and to a much lower extent
Table 1 Data collection and refinement statistics
Gi1/scFv16a
Data collection
Space group P2221
Cell dimensions (σ)
a, b, c (Å) 58.51, 104.74, 211.82
α, β, γ (°) 90.00, 90.00, 90.00
Resolution (Å) 39.26–2.00(2.07–2.00)b
Rsym or Rmerge 0.176(0.888)
I/σI 9.91(0.73)
Completeness (%) 99.16(99.47)
Redundancy 4.6(4.8)
Refinement
Resolution (Å) 39.26–2.00(2.07–2.00)
No. reflections 88,191(8710)
Rwork/Rfree 0.1746/0.2097(0.2682/0.2940)
No. atoms
Protein 7567
Ligand/ion 41
Water 628
B-factors (Å2)
Protein 47.08
Ligand/ion 31.55
Water 51.44
R.m.s. deviations
Bond lengths (Å) 0.007
Bond angles (°) 1.19
aThe data set was collected from one single crystal
bValues in parentheses are for highest-resolution shell
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Fig. 1 Isolation of mAb16 and its binding profile to each component. a Analytical SEC of rhodopsin/Gi1 with each antibody. Rhodopsin/Gi1 runs at 8.2 mL
and each mAb alone runs 8.4–9mL (c). Rhodopsin/Gi1 bound to mAb makes higher molecular weight product and migrates at the elution volume of 6–7
mL depending on the mAb. b Analytical SEC of rhodopsin/Gi1 with each antibody following to GTPγS treatment. Intact complex remains at 6–7mL only in
the mAb16 condition. c Analytical SEC of individual component of rhodopsin/Gi1 or heterotrimeric Gi1 with each antibody. Top left: Binding experiment with
Gαi1 subunit and each mAb. The peak of Gαi1 at 11 mL stays intact indicating there is no binding with each mAb. Top right: Binding experiment with opsin.
Both mAb peaks and Opsin peak (at 9.5 mL) stays intact. Bottom left: Binding experiment with Gβγ subunit. The peak of Gβγ at 11.2 mL disappears upon
incubating with mAbs except mAb16 and each mAb peak shifts towards left compared to the ones with Gαi1 or opsin indicating those mAbs recognize Gβγ
subunit as an epitope. Bottom right: Binding experiment with heterotrimeric Gi1
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(Fig. 4a). On the other hand, the binding of GDP is only modestly
affected when the complex is bound to Fab16 (Fig. 4a). Next we
examined the basal nucleotide exchange rate of Gi1 and Gi1/
Fab16 under conditions where GDP release is rate-limiting
(Fig. 4b). Fab16-bound Gi1 releases GDP ~1.5 to 2-fold slower
than Gi1 alone (Table 2). These findings suggest that in the
absence of a coupled GPCR, Fab16 stabilizes the heterotrimer in
its GDP-bound conformation. As a comparison, we examined the
effect of Nb35 that was originally developed against the β2AR/Gs
complex2. Structurally, it binds at the interface between switch II
and helix III of Gαs and Gβ1, and has been characterized to
provide GTPγS resistance to a GPCR/Gs complex. It’s been used
for structural studies of all GPCR/Gs-type complexes both in
crystallography and cryo-EM so far2,5–7. We monitored the
binding kinetics of GTPγS and GDP to the nucleotide-free β2AR/
Gs complex. BODIPY-FL-GTPγS binds to the complex with fast
kinetics in the absence of Nb35 but becomes extremely slow or
negligible when bound with Nb35 (Fig. 4c), presumably due to
the inhibition of the conformational change in switch II and
switch III. BODIPY-FL-GDP showed no detectable binding to the
complex alone or to the complex bound with Nb35 (Fig. 4c).
Generalization of mAb16 binding to other G-protein subtypes.
Because mAb16’s epitope is located on a short stretch of the αN
helix of the Gα subunit (Figs. 2a, b and 3a) as well as a small part
of the Gβ1 subunit that can complex with all Gα-protein subtypes,
we sought to engineer the αN helix of the other G-protein α-
subunits in order to generalize scFv16 binding to all G-protein
subtypes. Starting with the Gαs subunit, we generated a chimera
in which the αN helix was replaced by the equivalent region of
Gαi (GαsiN; residues 1–38 of Gαs replaced by residues 1–31 of
Gαi1) (Fig. 5a). The GαsiN protein forms a heterotrimer with the
Gβγ subunit and forms a stable complex with the β2AR (Fig. 5b).
The β2AR/GsiN complex can bind Fab16 and is largely protected
from dissociation induced by GTPγS, whereas β2AR/GsiN com-
plex alone dissociated almost completely under the same condi-
tion (Fig. 5b). We then used the same engineering approach to
transfer Fab16 binding ability to G11, a Gq family member, and
replaced the αN helix of Gα11 with that from Gαi1 (Gα11iN,
residues 1–35 of Gα11 replaced by residues 1–29 of Gαi1) (Fig. 5a).
The Gα11iN protein forms a heterotrimer with Gβγ subunit and
couples to form a stable complex with the M1 muscarinic acet-
ylcholine receptor (M1R) (Fig. 5c). The M1R/G11iN complex
alone dissociates upon incubation with GTPγS, whereas the M1R/
G11iN complex bound to Fab16 showed GTPγS resistance
(Fig. 5c) consistent with Gi/o and GsiN complexes. Negative stain
EM visualization of the M1R/G11iN complex reveals a mono-
disperse sample (Fig. 5d). These results demonstrate that Fab16
(or scFv16) can be used as a tool with broad variety of GPCR/G-
protein complexes by substituting the αN helix of other Gα-
subunit with equivalent region of Gαi1. Scanning the chimera
junction between Gα11 and Gαi1 shows that a smaller substitution
in the middle of the αN helix is still tolerated for the expression
and the heterotrimer formation (Supplementary Fig. 2a). When
replaced with the equivalent residues with this minimal chimeric
region (residues 1–18 of Gαi1), both Gs and G11 are enabled to
bind Fab16 and form stable complexes with respective GPCRs
(Supplementary Fig. 2b, c.) The same minimal region when
transferred to G12 also enables Fab16 binding (Supplementary
Fig. 2d). The binding interface of Gβ1 subunit to scFv16 is limited
compared to Gα subunit in the crystal structure. These residues
are mostly conserved among Gβ family members except Gβ5
(Supplementary Fig. 3). There is no direct interaction between
Gγ2 and scFv16 in the crystal structure. The fact that mAb16 was
originally raised against and indeed binds to Rhodopsin/Gi1 that
is composed of Gγ1 from the native bovine retina and still binds
G-proteins or GPCR/G-protein complexes composed of Gγ2
indicates that Fab/scFv16 binds to the heterotrimeric G-protein
regardless of the composition of the γ-subunit. Therefore, the
binding ability to Fab16 is transferable to broad range of G-
protein family members with minimal chimeric constructs. We
provide amino-acid sequences of G-protein chimera constructs in
the Supplementary Note 2 as well as the primers used for the
construction in the Supplementary Table.
Discussion
In this work, we have developed a unique antibody fragment that
recognizes an interface on heterotrimeric Gi1. The antibody
confers the GPCR–Gi/o complexes the resistance to GTPγS-
induced dissociation. This property is also observed with formerly
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Fig. 2 Crystal structure of Gi1/scFv16 and characterization of Fab16. a Overall structure of Gi1/scFv16 complex. Cartoon representation with Gαi1 in gold, Gβ
in cyan, Gγ in magenta, scFv-heavy chain in light grey and scFv-light chain in light blue. b Superposition of Gi1/scFv16 structure onto Gi1 (PDB: 1GP2) based
on alignment of Gβγ subunits. Gαi1 (1GP2) in grey and Gi1/scFv16 in the same colour code as in a. For clarity, Gβγ subunits and scFv16 is shown as
transparent cartoon. Arrows show a slight rotational displacement of Gαi1 towards Gβ1 compared to Gi1 alone. Additional interactions are formed between
switch I and switch II of Gαi1 and Gβ1. c Interaction between Gi1 and scFv16. The residues participating in the interactions are depicted with stick models in
the expanded panels. Residue numbers are shown with Common Gα Numbering (CGN) code for Gαi142
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identified Nb35 for Gs complexes2. Nb35 and mAb16 engage
distinct epitopes at the G-protein interface: Nb35 binds at the
switch II and αIII helix of Gαs and Gβ, while mAb16 engages the
αN helix of Gαi1 and Gβ. The switch II region adopts a distinct
conformation upon binding of GTPγS compared to the
nucleotide-free or GDP-bound state observed in the crystal
structures as well as in the EPR spectroscopic measurement2,20–23.
Nb35 is reported to suppress nucleotide exchange turnover of the
CTR/Gs complex5 and indeed it prevents GTPγS binding to the
β2AR/Gs complex (Fig. 4c), which we presume due to the fixed
conformation of the switch II in the nucleotide-free state and
steric clash of the switch III with Nb35. On the other hand,
mAb16 binds 40 Å away from the nucleotide-binding pocket with
no direct contact with this region yet prevents the binding of
GTPγS to the nucleotide-free GPCR/G-protein complex (Fig. 4a)
and helps heterotrimeric Gi1 to retain GDP in the nucleotide-
binding pocket (Fig. 4b). It has been reported that heterotrimer
formation rigidifies the switch II region that is in direct contact
with Gβ subunit23. Thus, by stabilizing interactions between the
Gβ subunit and switch II, mAb16 prevents GTPγS binding to the
empty pocket. This may also explain the slower GDP release as
Gβ subunit functions as a GDP dissociation inhibitor (GDI)24.
Additional interactions formed between switch I, II and Gβ1
subunit upon scFv16 binding supports this idea (Fig. 2b).
Another possibility would be inferred from HDX-MS measure-
ments that revealed the dynamic nature of αN-β1 junction of Gs
during the complex formation with β2AR and the dissociation
upon addition of GDP/AlF425. Binding of mAb16 would tighten
the association of αN helix with Gβ subunit and concomitantly
reduce the dynamics of αN–β1 junction, which may influence the
binding of nucleotide through the β1-strand and the P-loop that
is in direct contact with nucleotide. Previous work showing that
binding of GTPγS triggers release of αN helix from Gβ and
promotes its unfolding26 indicates that there could be an allos-
teric effect between the nucleotide-binding pocket and αN helix.
Contrary to the large diversity of different GPCR genes in the
human genome, there are only four major G-protein family
members: Gs, Gi/o, Gq/11 and G12/1327. Among them Gi/o is the
most broadly coupling G-protein10. mAb16 is originally raised
against rhodopsin/Gi1 complex and binds rhodopsin/Gi1, μOR/
Gi1 and M2R/GoA complexes, suggesting that it likely binds all
Gi/o type complexes, according to the sequence similarity of the
epitope residues and the binding profile of individual G-protein
alone (Fig. 3b). In contrast, the binding interface of Gαs to Nb35
is not conserved among Gα subtypes; therefore it would require
elaborate protein engineering to transfer the binding surface to
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other family members or to evolve the nanobody itself. On the
other hand, the binding surface of Gαi1 to mAb16 is located in a
small stretch of the αN helix. Since the αN helix apparently serves
as a separate module from the Ras-like domain to interact with
Gβγ, it is more amenable to generating functional chimeras28–30.
Previous studies have shown that the entire αN helix of Gαq, Gα12
and Gα13 can be substituted with the corresponding region of
Gαi1 to produce functional chimeric Gi/q, Gi/12 and Gi/13. These
engineered G proteins retained the biochemical properties of their
counterpart wild types, while αN helix of Gα12/13 is reportedly
important for the receptor selectivity31. Chimeric Gs protein has
also been made with various lengths of αN from Gαi subunit to
investigate the functional role of this region32,33. While the chi-
meras exhibit a large constitutive activity when the substitution
goes beyond αN helix to replace the residues 1–62 of Gαs by 1–54
of Gαi, a minor increase in the basal activity was observed when
residues 1–41 of Gαs is replaced by 1–34 of Gαi. Our substitutions
of GsiN and G11iN are both within the range of these chimeric
designs and therefore would be expected to behave in the same
way as the wild-type counterparts. In fact, our G protein chimeras
form functional heterotrimers with co-expressed Gβγ subunit and
form stable and functional complexes with cognate GPCRs. The
more conserved chimeras where the residues 1–18 of Gαi1 is
transferred to the equivalent residues of Gαs, Gα11 and Gα12 are
also able to bind with Fab16 (Supplementary Fig. 2).
In conclusion, the antibody fragment derived from mAb16
promotes the stabilization of GPCR/G-protein complexes and
adds an asymmetric feature that may aid with cryo-EM particle
projection alignment. The usefulness of the antibody fragment in
structural determination was proven by the cryo-EM structure of
μOR/Gi1 complex where the presence of scFv16 stabilized the
complex for high-resolution cryo-EM work. Furthermore, this
antibody fragment can be applied to other G-protein subtypes
with minimal protein engineering and therefore would be
expected to be a broadly applicable tool for cryo-EM studies of
any GPCR/G-protein complex.
Methods
Protein expression and purification. Rhodopsin/Gi1 complex was purified as
described previously16. Briefly, bovine rhodopsin with three mutations, N2C,
M257Y and N282C, was stably expressed in and purified from HEK293S GnTI−
cells using 1D4 immunoaffinity chromatography. Purified rhodopsin was incu-
bated with Gi1 reconstituted from recombinant Gαi1 subunit from Escherichia coli
BL21 (DE3) cells (Novagen) and Gβγ subunit purified from bovine retina (W L
Lawson Company). Rhodopsin/Gi1 complex formation was triggered by the irra-
diation through 495 nm long-pass filter in the presence of apyrase (Sigma-Aldrich).
Rhodopsin/Gi1 complex was separated from the free rhodopsin or Gi1 by SEC on a
Tricorn 10/600 column packed with Superdex 200 (GE healthcare) in a buffer
containing 100 mM NaCl, 20 mM Hepes pH 7.5, 0.01% lauryl maltose neopentyl
glycol (MNG), 2 mM 2-mercaptoethanol.
µOR with a cleavable amino and carboxy-terminal FLAG- and His-tag13 was
expressed in Spodoptera frugiperda Sf9 insect cells using baculovirus infection
system (Expression Systems). Cells were solubilized in 1% n-dodecyl-β-D-maltoside
(DDM) (Anatrace), 0.2% 5-cholesterol hemisuccinate (CHS) (Steraloids) and the
soluble fraction was purified by Ni-chelating sepharose chromatography. The
eluted protein was supplemented with 2 mM CaCl2, loaded onto M1 anti-FLAG
immunoaffinity column (prepared in house) and washed with progressively lower
concentrations of the antagonist naloxone (Sigma-Aldrich). Receptor was eluted in
a buffer consisting of 100 mM NaCl, 20 mM Hepes pH 7.5, 0.1% DDM, 0.01% CHS
with 50 nM naloxone, and further purified by SEC on a Superdex 200 10/300
column in a buffer containing 1 µM lofentanil (Tronto Research Chemicals) to
exchange the ligand. Monomeric fractions were pooled, further supplemented with
a twofold molar excess of lofentanil and concentrated to ~100 µM for complex
formation.
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Fig. 4 Nucleotide-binding kinetics. a Influence of Fab16 on the nucleotide-binding kinetics of the purified M2R/GoA complex. Nucleotide binding was
monitored by using BODIPY-FL-GTPγS or BODIPY-FL-GDP. b Influence of Fab16 on the nucleotide release kinetics of Gi1. GDP release was monitored by
BODIPY-FL-GTPγS- or BODIPY-FL-GDP-binding kinetics under conditions where GDP release is the rate-limiting step. c Nucleotide binding to β2AR/Gs
complex in the presence or absence of Nb35. The curves represent the mean ± standard error of three experiments
Table 2 Effect of Fab16 or Nb35 on the nucleotide-binding/releasing rate
M2R/GoA+GTPγS M2R/GoA+ Fab16+GTPγS M2R/GoA+GDP M2R/GoA+ Fab16+GDP
k (1/s) 0.061 ± 0.002 (fast)a 0.00092 ± 0.00004 0.00244 ± 0.00003 0.00042 ± 0.00009
k (1/s) 0.0032 ± 0.0002 (slow)a
Gi1+GTPγS Gi1+ Fab16+GTPγS Gi1+GDP Gi1+Gab16+GDP
k (1/s) 0.00206 ± 0.00003 0.00116 ± 0.00003 0.0115 ± 0.0002 0.00572 ± 0.00007
β2AR/Gs+GTPγS β2AR/Gs+Nb35+GTPγS β2AR/Gs+GDP β2AR/Gs+Nb35+GDP
k (1/s) 0.00327 ± 0.00005 ND ND ND
All values are expressed as mean ± s.e.m. of triplicate experiments
aThe binding kinetics was best fit and analysed by two phase association. The fraction corresponding to the fast component is 0.526 ± 0.005
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β2AR was purified in the same way as described previously34. Briefly, Sf9 insect
cells were lysed by osmotic shock prior to solubilization of the membrane fraction
by DDM. Solubilized receptor was first purified by M1 anti-FLAG immunoaffinity
chromatography, followed by alprenolol-sepharose chromatograpy (alprenolol-
sepharose resin prepared in house) to isolate only functional receptor. Alprenolol-
sepharose eluate was concentrated on M1 FLAG affinity resin, and then washed
with ligand-free buffer for 1 h at room temperature to eliminate bound alprenolol.
Receptor was eluted in a buffer consisting of 20 mM Hepes pH 7.5, 350 mM NaCl,
0.1 % DDM and 0.01% CHS and further purified by size-exclusion
chromatography on a Superdex 200 10/300 column (GE Healthcare) in buffer
containing 20 mM Hepes pH 7.5, 100 mM NaCl, 0.05 % DDM, 0.005% CHS and 1
µM BI-167107 (Boehringer-Ingelheim). The eluated receptor was concentrated to
~100 µM for complexing.
For M1R and M2R, we used constructs used in previous studies12,35 with some
modifications. Briefly, T4L in the ICL3 of M1R was removed, and residues 219–232
and 345–354 were added to TM5 and TM6, respectively. The ICL3 of M2R was
extended by 15 amino-acid residues from TM6. Primer sequences for these
modifications are provided in the Supplementary Table. The amino-acid sequences
for these receptors are provided in the Supplementary Note 2. These receptors were
purified essentially in the same way as µOR with detergent exchange to MNG
during M1 FLAG chromatography and using atropine (Sigma-Aldrich) and
iperoxo (Sigma-Aldrich) in place of naloxone and lofentanil, respectively.
Heterotrimeric G-proteins were expressed and purified as previously described.
Briefly, Trichuplusia ni (Hi5) insect cells (Expression Systems) were co-infected
with two viruses, one encoding the wild-type human Gα subunit and another
encoding the wild-type human β1γ2 subunits with an decahistidine tag inserted at
the amino terminus of the β1 subunit with HRV-3C protease cleavable site. In the
case of G11iN, additional virus encoding Ric8A was also co-infected. Cells were
harvested 48 h post infection, lysed in hypotonic buffer and lipid-modified
heterotrimeric G-protein was extracted in a buffer containing 1% sodium cholate
(Sigma-Aldrich) and 0.05% DDM. The soluble fraction was purified using Ni-
chelating sepharose chromatography, and the detergent was exchanged from
cholate/DDM mixture to DDM alone. After elution, HRV-3C protease (in-house
prepared) was added and the protein was dialyzed against a buffer containing 20
mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl2, 0.05% DDM, 100 μM Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) (Sigma-Aldrich), 10 μM GDP
(Sigma-Aldrich). Cleaved heterotrimeric G-protein was further purified by
reloading over Ni-sepharose resin. The flow through was collected and purified
over a size-exclusion chromatography using a Superdex 200 10/300 column.
Soluble Gβγ subunit for crystallography was expressed and purified from
Trichuplusia ni (Hi5) insect cells. Hi5 cells were infected with baculovirus encoding
the human β1γ2 subunits with cysteine 68 of γ2 subunit mutated to serine
(Gβ1γ2C68S) to remove the geranylgeranylation modification. A decahistidine tag
was attached at the amino terminus of the β1 subunit with HRV-3C protease
cleavable site. Cultures were harvested 48 h post infection. Cells were lysed in the
lysis buffer (10 mM Tris pH 7.4, 5 mM 2-mercaptoethanol, 160 μg/mL
benzamidine and 2.5 μg/mL leupeptin). Following to the centrifugation, the
supernatant was incubated with Ni-chelating sepharose. The resin was first washed
with a high salt buffer (20 mM Hepes pH 7.5, 500 mM NaCl, 20 mM imidazole and
2 mM 2-mercaptoethanol) then a low salt buffer (20 mM Hepes pH 7.5, 100 mM
NaCl, 20 mM imidazole and 100 μM TCEP). The protein was eluted with an
elution buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 250 mM imidazole and 100
μM TCEP) and dialysed against 20 mM Hepes pH 7.5, 100 mM NaCl and 100 μM
TCEP after adding HRC-3C protease to cleave amino-terminal His-tag.
Gβ1γ2C68S was further purified by reloading over Ni-sepharose resin. The flow
through was collected and purified by a size-exclusion chromatography using a
Superdex 200 10/300 column.
The human Gαi1 protein for crystallography was expressed in Escherichia coli
Rosetta2 (DE3) cells (Novagen) with an N-terminal octahistidine-tag and an HRV-
3C protease recognition site. The culture was grown at 37 °C in TB medium. When
the OD 600 reached 0.6, the protein expression was induced with 0.5 mM IPTG
and further grown for 20 h at 24 °C. The cells were harvested by centrifugation,
resuspended in the lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM
imidazole, 0.1 mM PMSF, 10 μM GDP and 5 mM 2-mercaptoethanol). The
resuspended cells were disrupted by sonication. Cell lysate was clarified by
centrifugation and the supernatant was incubated with Ni-chelating sepharose
equilibrated with the lysis buffer. The resin was first washed with the high salt
buffer (20 mM Hepes pH 7.5, 500 mM NaCl, 1 mM MgCl2, 20 mM imidazole, 10
μMGDP and 2mM 2-mercaptoethanol) then the low salt buffer (20 mM Hepes pH
7.5, 100 mM NaCl, 1 mM MgCl2, 20 mM imidazole, 10 μM GDP and 100 μM
TCEP). The protein was eluted with the elution buffer (20 mM Hepes pH 7.5, 100
mM NaCl, 1 mM MgCl2, 250 mM imidazole, 10 μM GDP and 100 μM TCEP) and
dialysed against 20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl2, 10 μM GDP
and 100 μM TCEP after adding HRC-3C protease to cleave amino-terminal tag.
Cleaved Gαi1 was further purified by reloading over Ni-sepharose resin. The flow
through was collected and purified over a size-exclusion chromatography using a
Superdex 200 10/300 column.
GPCR/G-protein complex was prepared essentially in the same way as
described previously using agonists lofentanil, iperoxo, BI-167107 for μOR, M1R
and M2R, β2AR, respectively2. Briefly, receptor was mixed with 1.2–1.5 molar
excess G-protein. Following the incubation at room temperature for 1 h, apyrase
was added and the reaction mixture was transferred to 4 °C and further incubated
for 4 h to overnight. Prior to loading M1 FLAG column, 1% MNG and 0.1% CHS
was added. The MNG concentration was progressively lowered during M1 FLAG
wash. FLAG eluted protein was further purified by size-exclusion chromatography
on a Superdex 200 10/300 column.
Monoclonal antibody production and characterization. For the antigen,
rhodopsin–Gi1 complex was stabilized by crosslink using BS-3 (ThermoFisher).
Naval Medical Research Institute (NMRI) mice were immunized intraperitoneally
with the emulsified antigen. (This study was carried out in strict accordance with
the Rules and Regulations for the Protection of Animal Rights (Tierschutzver-
ordnung) of the Swiss Bundesamt für Veterina ̈rwesen. The protocol was ethically
approved by the Ethikkommission beider Basel (Permit Number: 237/23523).)
Mice with strong ELISA reaction to the antigen were killed and the spleen was
removed. Isolated splenocytes were fused with the myeloma cell partner (PAI
Gai1 MGCTLSAEDKAAVERSKMIDRNLREDGEKAAREV
Gas MGCLGNSKTEDQRNEEKAQREANKKIEKQLQKDKQVYRATH
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Fig. 5 Generation of chimeric G-proteins. a Alignment of the αN helix of the
G-protein subfamilies and the sequence of the chimeric Gα subunits.
Transferred region from Gαi1 in each chimera is colored in orange.
b, c Analytical SEC of β2AR/GsiN and M1R/G11iN complexes incubated with
GTPγS in the presence or absence of Fab16. Protein elution profiles were
monitored by the intrinsic tryptophan fluorescence. d Negative stain
electron microscopy image of purified the M1R/G11iN/scFv16 complex
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mouse myeloma cells, derived from P3-x63-AG8) using polyethylene glycol 1500
(Roche Diagnostics). The fusion mixture was plated into multi-well plates (Thermo
Scientific Nunc MicroWell Cell Culture High Flange 96-Well Microplates) and
clonal hybridomas were selected by growing in HAT medium supplemented with
culture supernatant of mouse macrophages P388. IgG positive clones were screened
by ELISA for reactivity against Rhodopsin/Gi1 complex. Clones that showed a
positive reaction in an ELISA assay and by immunoprecipitation were further
characterized as monoclonal antibodies or Fab fragments. Initial SEC analysis using
rhodopsin/Gi1 or each component was carried out in 20 mM Hepes pH 7.5,
100 mM NaCl, 2 mM 2-mercaptethanol and 0.01% MNG using Superdex 200
10/200 column.
Coding regions of the heavy-chain (VH-CH1) and light-chain (VL-CL) of
mAb16 were cloned into the modified pVL1392 vector where VH-CH1 and VL-CL
both attached with GP67 secretion signal sequence were under polyhedron and p10
promoter regulation, respectively. Octahistidine-tag with HRV-3C protease
cleavable site was attached to the carboxy-terminus of VH-CH1 for the
purification. The single-chain variable fragment of mAb16 (scFv16) was cloned
into a modified pVL1392 vector containing a GP67 secretion signal immediately
prior to the amino terminus of the scFv16. Octahistidine-tag with HRV-3C
protease cleavable site was attached to the carboxy-terminus.
Both Fab16 and scFv16 were expressed in secreted form from Trichuplusia ni
Hi5 insect cells using the baculovirus infection method (Expression Systems),
and purified by Ni-sepharose chromatography. Supernatant from baculovirus
infected cells was pH balanced by addition of Tris pH 7.5. Chelating agents were
quenched by addition of 1 mM nickel chloride and 5 mM calcium chloride and
incubation with stirring for 1 h at 25 °C. Resulting precipitates were removed by
centrifugation and the supernatant was loaded over Ni-sepharose
chromatography column. The column was washed with a high salt buffer
(20 mM Hepes pH 7.5, 500 mM NaCl and 20 mM imidazole) followed by a low
salt buffer (20 mM Hepes pH 7.5, 100 mM NaCl and 20 mM imidazole). The
protein was eluted with the elution buffer (20 mM Hepes pH 7.5, 100 mM NaCl
and 250 mM imidazole) and the carboxy-terminal octahistidine tag was cleaved
by incubation with HRV-3C protease during dialysis against a buffer consisting
of 20 mM Hepes pH 7.5 and 100 mM NaCl. Cleaved protein was further purified
by reloading over Ni-NTA resin. The flow through was collected and purified
over a size-exclusion chromatography using a Superdex 200 16/60 column (GE
healthcare). Monomeric fractions were pooled, concentrated and flash frozen in
liquid nitrogen until use.
For the binding assay of Fab16 with heterotrimeric G-protein subtypes, Fab16
was first labelled with Alexa Fluor 488 NHS Ester (ThermoFisher Scientific) in
20 mM MES pH 6.5. Free dye was removed by G-50 desalting column (GE
healthcare), and the labelled Fab16 was recovered and concentrated. 5–30 μM of G-
protein was mixed with 0.4 μM of labelled Fab16, incubated for 1 h and run on SEC
on a Superdex 200 10/300 column. Fluorescence signal was recorded with
excitation at 488 nm and emission at 512 nm.
Construction of chimeric G proteins. GαsiN was constructed by substituting the
residues 1–38 of Gαs with the residues 1–31 of Gαi1. Gα11iN were constructed by
substituting the residues 1–36 of Gα11 with the residues 1–29 of Gαi1. These
constructs were cloned into pFastBac1 vector and baculovirus were made according
to the manufacturer. Scanning chimeras of Gα11 as well as GαsiN18, Gα11iN18 and
Gα12iN18 are also made in the same way. Primer sequences used to construct the
chimeras are provided in the Supplementary Table. The amino-acid sequences of
the chimera constructs are provided in the Supplementary Note 2.
Characterizing resistance to GTPγS. GTPγS resistance test was performed in the
buffer containing 20 mM Hepes pH7.5, 100 mM NaCl, 100 μM TCEP, 0.01%
MNG, with each agonist for the complex, lofentanil, iperoxo, BI167107 for μOR/
Gi1, M1R/G11iN and M2R/GoA, β2AR/GsiN, respectively. Purified complex with or
without Fab16 was incubated with 100 μM GTPγS in the buffer and incubated for
1 h at 24 °C followed by SEC analysis on Superdex 200 10/300 monitoring the
protein intrinsic fluorescence with the excitation wavelength at 280 nm and
emission wavelength 340 nm.
Determination of the structure of the Gi1/scFv16 complex. For Gi1/scFv16
crystallization, separately purified and concentrated Gαi1, Gβ1γ2C68S and scFv16
were mixed at a 1:1:1.2 molar ratio and incubated for 30 min at 24 °C. The resulting
Gi1/scFv16 complex was purified from uncomplexed subunits and free scFv16 by
SEC in the buffer containing 20 mM Hepes pH7.5, 100 mM NaCl, 1 mM MgCl2,
10 μM GDP and 100 μM TCEP. Purified Gi1/scFv16 was incubated with 1 mM
aluminium chloride and 50 mM sodium fluoride for 1 h on ice, concentrated to
10–15 mg/mL and crystallized using the hanging drop vapour diffusion method at
20 °C against a reservoir solution containing 10% PEG 8000, 0.1 M Sodium citrate
pH 5.0, 1 mM MgCl2, 10 μM GDP, 100 μM TCEP, 1 mM aluminium chloride and
10 mM sodium fluoride. Crystals appeared within a few hours and grew to the full
size in 5 days. Crystals were soaked into the reservoir solution supplemented with
25% glycerol as a cryo-protectant and flash frozen in liquid nitrogen. The X-ray
data set was collected at the experimental station 12-2 in the Stanford Synchrotron
Radiation Lightsource. Diffraction data were integrated by XDS36, scaled and
merged by AIMLESS37. The structure was solved by the molecular replacement in
Phaser38 using the heterotrimeric Gi-protein (1GP2) and scFv fragment (4NKD) as
independent search models. Manual model building was performed in Coot39 and
refinement was performed with Phenix refine40,41. Ramachandran statistics are
favoured 96.6%, allowed 3.4%, outlier 0.0%.
Nucleotide-binding studies. For the nucleotide-binding experiment, fluorescence
from BODIPY-FL-GTPγS or BODIPY-FL-GDP (ThermoFisher Scientific) was
recorded using the Fluorolog spectrophotometer (HORIBA) in the 500 μL quartz
cuvette. The fluorophore was exited at 495 nm and emission was detected at
508 nm at 22 °C. The buffer composition is 20 mM HEPES, pH 7.5, 100 mM
sodium chloride, 0.01% LMNG, 10 mM magnesium chloride, 100 μM TCEP and
10 μM iperoxo or BI-167107 for GPCR/G-protein complexes, and 20 mM HEPES,
pH 7.5, 100 mM sodium chloride, 0.02% DDM, 10 mM magnesium chloride,
100 μM TCEP for Gi1. Kinetics data were collected with 1 μM fluorophore alone
for 100 s to establish the baseline fluorescence intensity. Protein was added to
200 nM and rapidly mixed in the fluorescence cuvette. Data points were acquired
every second for 600 s. The resulting kinetics spectra were plotted and fit to one
phase- or two phase-association function using GraphPad Prism 7.0.
Data availability. Data supporting the findings of this manuscript are available
from the corresponding authors upon reasonable request. Structure and data set in
this work have been deposited in the Protein Data Bank under accession code PDB
6CRK.
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